A systematic review on the excess health risk of antibiotic-resistant bloodstream infections for six key pathogens in Europe

Hassoun-Kheir, Nasreen; Guedes, Mariana; Ngo Nsoga, Marie-Therese; Argante, Lorenzo; Arieti, Fabiana; Gladstone, Beryl P.; Kingston, Rhys; Naylor, Nichola R.; Pezzani, Maria D.; Pouwels, Koen B.; Robotham, Julie V.; Rodríguez-Baño, Jesús; Tacconelli, Evelina; Vella, Venanzio; Harbarth, Stephan; de Kraker, Marlieke E.A.; Barana, Benedetta; Cappelli, Eva; De Rui, Maria Elena; El-Abasiri, Radwa A.; Galia, Liliana; Geurtsen, Jeroen; Mejia, Jorly; Palladino, Andrea; Piljic, Alen; Rajendran, Nithya Babu; Reyna-Villasmil, Eduardo; Schmidt, Johannes E.

doi:10.1016/j.cmi.2023.09.001

Cited by 5 publications

(3 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median time to bloodstream infection onset from admission was one [0-15] and four days [1][2][3][4][5][6][7][8] for adults and pediatric patients, respectively. Adults and pediatric patients were critically ill in 14.2% and 60% of the cases, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…Bloodstream infection is a serious clinical condition associated with increased mortality despite the development of new antibiotics and supportive therapies. Gram-negative bacilli are frequently involved in this kind of infection with their effects, which are strongly influenced by the type of pathogen and burden of drug resistance [1], patient conditions and rapidity and appropriateness of diagnosis and treatment [2,3]. Among Enterobacterales, carbapenem-resistant Escherichia coli and Klebsiella pneumoniae are often the target of surveillance programs and studies, and the literature provides numerous elements on which to base the clinical and diagnostic management of patients with infections sustained by these pathogens [1].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bloodstream Infections by Pantoea Species: Clinical and Microbiological Findings from a Retrospective Study, Italy, 2018–2023

Casale,

Boattini,

Bianco

et al. 2023

Antibiotics

View full text Add to dashboard Cite

(1) Background: The widespread use of MALDI-TOF coupled to mass spectrometry has improved diagnostic accuracy by identifying uncommon bacteria. Among Enterobacterales, Pantoea species have been seen to be implicated in several human infections, but their clinical and microbiological framework is currently based on a few anecdotal reports. (2) Methods: We conducted this five-year (2018–2023) single-center study aimed at investigating the prevalence and clinical and microbiological findings of Pantoea species bloodstream infections. (3) Results: Among the 4996 bloodstream infection Gram-negative isolates collected during the study period, Pantoea species accounted for 0.4% (n = 19) of isolates from 19 different patients, 5 of them being pediatric cases. Among Pantoea species isolates, P. agglomerans was the most frequently detected (45%; n = 9) followed by P. eucrina (30%; n = 6) and P. septica (15%; n = 3). Malignancy (35.7%) in adults and malignancy (40%) and cerebrovascular disease following meconium aspiration (40%) in pediatric patients as comorbidities and shivering and/or fever following parenteral infusion (36.8%) as a symptom/sign of Pantoea species bloodstream infection onset were the most frequently observed clinical features. Among adults, primary bloodstream infection was the most frequent (50%), whereas among pediatric patients, the most commonly identified sources of infection were catheter-related (40%) and the respiratory tract (40%). Overall, Pantoea species bloodstream infection isolates displayed high susceptibility to all the antibiotics except for ampicillin (63.2%), fosfomycin (73.7%), and piperacillin/tazobactam (84.2%). Targeted antibiotic treatment was prescribed as monotherapy for adults (71.4%) and combination therapy for pediatric patients (60%). The most prescribed antibiotic regimens were piperacillin/tazobactam (21.4%) in adults and meropenem- (40%) and aminoglycoside-containing (40%) antibiotics in pediatric patients. The overall 28-day all-cause mortality rate was 5.3% (n = 1). (4) Conclusions: The prevalence and 28-day mortality rate of Pantoea species bloodstream infections were low. The prescription of targeted therapy including broad-spectrum antibiotics could indicate an underestimation of the specific involvement of the Pantoea species in the onset of the disease, warranting further studies defining their pathogenic potential.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Bloodstream Infections by Pantoea Species: Clinical and Microbiological Findings from a Retrospective Study, Italy, 2018–2023

Casale,

Boattini,

Bianco

et al. 2023

Antibiotics

View full text Add to dashboard Cite

show abstract

“…Meanwhile, Enterococcus faecium and E. faecalis are frequent agents of several nosocomial infections, including severe cases of bacteremia, with strongly reduced therapeutic options. Despite limited data about the incidence of infections by enterococci in hospitals, a higher mortality of bloodstream infections with VREs (independent of species) in comparison to susceptible enterococci has been reported recently [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Enterococci, Van Gene-Carrying Enterococci, and Vancomycin Concentrations in the Influent of a Wastewater Treatment Plant in Southeast Germany

Geissler,

Schröttner,

Oertel

et al. 2024

Microorganisms

View full text Add to dashboard Cite

Vancomycin-resistant (VR) Enterococcus spp. can be detected in high concentrations in wastewaters and pose a risk to public health. During a one-year study (September 2022–August 2023), 24 h composite raw wastewater samples (n = 192) of a municipal wastewater treatment plant were investigated for cultivable enterococci. After growth on Slanetz–Bartley agar (SBA), a mean concentration of 29,736 ± 9919 cfu/mL was calculated. Using MALDI-TOF MS to characterize randomly picked colonies (n = 576), the most common species were found to be Enterococcus faecium (72.6%), E. hirae (13.7%), and E. faecalis (8.0%). Parallel incubation of wastewater samples on SBA and VRESelect agar resulted in a mean rate of VR enterococci of 2.0 ± 1.5%. All the tested strains grown on the VRESelect agar (n = 172) were E. faecium and carried the vanA (54.6%) or vanB gene (45.4%) with limited sequence differences. In susceptibility experiments, these isolates showed a high-level resistance to vancomycin (>256 µg/mL). Concentration of vancomycin was determined in 93.7% of 112 wastewater samples (mean: 123.1 ± 64.0 ng/L) and varied between below 100 ng/L (the detection limit) and 246.6 ng/L. A correlation between the concentration of vancomycin and the rate of VR strains among the total enterococci could not be found. The combination of incubation of samples on SBA and a commercial vancomycin-containing agar applied in clinical microbiology with a multiplex PCR for detection of van genes is an easy-to-use tool to quantify and characterize VR Enterococcus spp. in water samples.

show abstract

An overview of sulbactam‐durlobactam approval and implications in advancing therapeutics for hospital‐acquired and ventilator‐associated pneumonia by acinetobacter baumannii‐calcoaceticus complex: A narrative review

Anand,

Verma,

Kaur

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

PurposeInfections caused by Acinetobacter baumannii, particularly those resistant to antibiotics such as carbapenem, have become a global health crisis with a significant mortality rate. Hospital‐acquired pneumonia (HAP) and ventilator‐associated pneumonia (VAP) resulting from the A. baumannii‐calcoaceticus (ABC) complex represent a major clinical challenge. This review aimed to understand the approval process, mechanism of action, therapeutic potential, and future implications of sulbactam‐durlobactam therapy (SUL‐DUR).MethodsPubMed, Web of Science, EMBASE, Clinical trials. gov, ICTRP, and CENTRAL were searched for studies on SUL‐DUR for the treatment of hospital‐acquired pneumonia and ventilator‐associated pneumonia. Also, World Health Organization, U.S. Food and Drug Administration, and Centers for Disease Control and Prevention websites were searched for relevant information.ResultsSUL‐DUR, marketed as Xacduro, is a novel pharmaceutical combination that functions as a narrow‐spectrum parenterally administered antibiotic. Sulbactam acts as a β‐lactamase inhibitor, whereas durlobactam protects against degradation by A. baumannii enzymes. A phase 1 trial successfully established the safety and tolerability of SUL‐DUR in patients with normal and mild renal impairment. A phase 2 trial demonstrated the safety and tolerability of SUL‐DUR in a larger population with urinary tract infections. A phase 3 trial showed that SUL‐DUR was non‐inferior to colistin in terms of mortality in A. baumannii‐related VAP, HAP, and bacteremia.ConclusionThe combination of sulbactam and durlobactam is a promising treatment option for HAP and VAP caused by ABC complex.

show abstract

A systematic review on the excess health risk of antibiotic-resistant bloodstream infections for six key pathogens in Europe

Cited by 5 publications

References 71 publications

Bloodstream Infections by Pantoea Species: Clinical and Microbiological Findings from a Retrospective Study, Italy, 2018–2023

Bloodstream Infections by Pantoea Species: Clinical and Microbiological Findings from a Retrospective Study, Italy, 2018–2023

Enterococci, Van Gene-Carrying Enterococci, and Vancomycin Concentrations in the Influent of a Wastewater Treatment Plant in Southeast Germany

An overview of sulbactam‐durlobactam approval and implications in advancing therapeutics for hospital‐acquired and ventilator‐associated pneumonia by acinetobacter baumannii‐calcoaceticus complex: A narrative review

Contact Info

Product

Resources

About